Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a potentially fatal hematologic malignancy (blood cancer). Data from the study showed that IPI-145 was clinically active, with an overall response rate of 73 percent, including three complete responses, among patients receiving IPI-145 dosed at ≤ 25 mg twice daily (BID). Data also showed that 53 percent of patients remained progression free for over one year. These data support DYNAMO, the ongoing Phase 2 study of IPI-145 in patients with refractory iNHL. These findings were presented today at the 55th Annual Meeting of the American Society of Hematology (ASH).
“Despite improvements in the treatment of indolent lymphoma, better therapies are needed for patients with resistant disease. Targeted agents such as IPI-145 have the potential to be used alone and in combination with existing therapies and may replace the use of chemotherapy, possibly changing the way patients with these malignancies are treated,” commented Ian Flinn, M.D., Ph.D., director, hematologic malignancies program, Sarah Cannon Research Institute, and an investigator for the trial. “I’m excited by the activity seen in this heavily pre-treated population of patients in this Phase 1 study with indolent non-Hodgkin lymphoma. The 73 percent overall response rate reported, including complete responses, is promising.”
Additionally, Infinity presented translational data showing that IPI-145 affects key signaling molecules in the tumor microenvironment, providing a potential mechanistic rationale underlying the clinical activity of IPI-145 observed in both iNHL and chronic lymphocytic leukemia (CLL).
“These results in patients with relapsed/refractory indolent non-Hodgkin lymphoma reinforce Infinity’s vision for IPI-145,” stated Julian Adams, Ph.D., president of R&D at Infinity. “We believe IPI-145 has the potential to become the best treatment for patients with indolent non-Hodgkin lymphoma, which is why we’re excited about continuing to advance IPI-145 in DYNAMO.”